DDInter667 DDInter1840
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Erlotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) upregulates {v} (Gene) CBLB
CBLB {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) downregulates {v} (Gene) BAG3
BAG3 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) upregulates {v} (Gene) STAP2
STAP2 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) downregulates {v} (Gene) MT2A
MT2A {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) binds {v} (Gene) EGFR
EGFR {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) covaries with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib {u} (Compound) downregulates {v} (Gene) EZH2
EZH2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Erlotinib (Compound) upregulates CBLB (Gene) and CBLB (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) upregulates STAP2 (Gene) and STAP2 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) downregulates MT2A (Gene) and MT2A (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) binds EGFR (Gene) and EGFR (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) covaries with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Erlotinib (Compound) downregulates EZH2 (Gene) and EZH2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)